HeartGenetics

HeartGenetics

Lisbon, Portugal· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

HeartGenetics is a Lisbon-based, ISO-certified digital health and diagnostics company that translates genetic data into actionable health reports through its proprietary HEARTDECODE software system. Its business is built on three pillars: Preventive Genetics (nutrition, fitness, wellness), Cardiovascular Genetics (thrombophilia risk), and Pharmacogenomics (personalized drug response). The company serves both consumers and healthcare specialists, positioning itself at the intersection of genetic testing, software analytics, and personalized medicine to drive value-based healthcare.

CardiovascularMetabolic & NutritionNeurology & PsychiatryGeneral Wellness

Technology Platform

Proprietary HEARTDECODE software system for intelligent genetic data analysis and reporting, integrated with an ISO-certified genetic testing laboratory.

Funding History

2
Total raised:$3M
Series A$2.5M
Seed$500K

Opportunities

The growing global adoption of pharmacogenomics in clinical practice and the expanding consumer market for personalized wellness present significant growth avenues.
Partnerships with healthcare providers, nutritionists, and pharmaceutical companies can drive integration and scale.

Risk Factors

The company faces regulatory evolution in genetic testing (e.g., EU IVDR), intense competition from larger genetic testing firms, and the challenge of driving widespread clinical adoption of its pharmacogenomic tools beyond early adopters.

Competitive Landscape

HeartGenetics competes with large direct-to-consumer genetic firms (e.g., 23andMe) in wellness, and with specialized clinical diagnostic labs and larger pharmacogenomic companies (e.g., OneOme, Thermo Fisher's PGx offerings) in its medical segments. Its differentiation lies in its integrated lab-software platform and specific cardiovascular expertise.